These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 10397388)

  • 21. Altered expression of interleukin-1 receptor antagonist in different stages of mouse skin carcinogenesis.
    La E; Muga SJ; Locniskar MF; Fischer SM
    Mol Carcinog; 1999 Apr; 24(4):276-86. PubMed ID: 10326864
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aspirin-induced increases in soluble IL-1 receptor type II concentrations in vitro and in vivo.
    Daun JM; Ball RW; Burger HR; Cannon JG
    J Leukoc Biol; 1999 Jun; 65(6):863-6. PubMed ID: 10380911
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transcriptional regulation of intracellular IL-1 receptor antagonist gene by IL-1 alpha in primary mouse keratinocytes.
    La E; Fischer SM
    J Immunol; 2001 May; 166(10):6149-55. PubMed ID: 11342635
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regulation of prostaglandin production in intact fetal membranes by interleukin-1 and its receptor antagonist.
    Brown NL; Alvi SA; Elder MG; Bennett PR; Sullivan MH
    J Endocrinol; 1998 Dec; 159(3):519-26. PubMed ID: 9834469
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The IL-1 system in HIV infection: peripheral concentrations of IL-1beta, IL-1 receptor antagonist and soluble IL-1 receptor type II.
    Kreuzer KA; Dayer JM; Rockstroh JK; Sauerbruch T; Spengler U
    Clin Exp Immunol; 1997 Jul; 109(1):54-8. PubMed ID: 9218824
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interleukin 1 receptor antagonist in human epidermis and cultured keratinocytes.
    Gruaz-Chatellard D; Baumberger C; Saurat JH; Dayer JM
    FEBS Lett; 1991 Dec; 294(1-2):137-40. PubMed ID: 1720743
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of interleukin-1 receptors and their role in interleukin-1 actions in murine microglial cells.
    Pinteaux E; Parker LC; Rothwell NJ; Luheshi GN
    J Neurochem; 2002 Nov; 83(4):754-63. PubMed ID: 12421347
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential regulation of bradykinin receptor density, intracellular Ca2+, and prostanoid release in skin and foreskin fibroblasts. Effects of cell density and interleukin-1alpha.
    Ochsenbein RM; Inaebnit SP; Luethy CM; Wiesmann UN; Oetliker OH; Honegger UE
    Br J Pharmacol; 1999 May; 127(2):583-9. PubMed ID: 10385262
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interleukin-1beta, interleukin-1 receptor antagonist, and interleukin-1 soluble receptor II in temporomandibular joint synovial fluid from patients with chronic polyarthritides.
    Alstergren P; Benavente C; Kopp S
    J Oral Maxillofac Surg; 2003 Oct; 61(10):1171-8. PubMed ID: 14586853
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lipopolysaccharide of Aggregatibacter actinomycetemcomitans up-regulates inflammatory cytokines, prostaglandin E2 synthesis and osteoclast formation in interleukin-1 receptor antagonist-deficient mice.
    Mizutani H; Ishihara Y; Izawa A; Fujihara Y; Kobayashi S; Gotou H; Okabe E; Takeda H; Ozawa Y; Kamiya Y; Kamei H; Kikuchi T; Yamamoto G; Mitani A; Nishihara T; Noguchi T
    J Periodontal Res; 2013 Dec; 48(6):748-56. PubMed ID: 23586622
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor necrosis factor-alpha induces interleukin-1 alpha and interleukin-1 receptor antagonist production by cultured human keratinocytes.
    Kutsch CL; Norris DA; Arend WP
    J Invest Dermatol; 1993 Jul; 101(1):79-85. PubMed ID: 8331299
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interleukin-1 receptor antagonist in normal and psoriatic epidermis.
    Hammerberg C; Arend WP; Fisher GJ; Chan LS; Berger AE; Haskill JS; Voorhees JJ; Cooper KD
    J Clin Invest; 1992 Aug; 90(2):571-83. PubMed ID: 1386612
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Production of intracellular IL-1alpha, IL-1beta, and IL-1Ra isoforms by activated human dermal and synovial fibroblasts: phenotypic differences between human dermal and synovial fibroblasts.
    Maret M; Chicheportiche R; Dayer JM; Gabay C
    Cytokine; 2004 Mar; 25(5):193-203. PubMed ID: 15036245
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential binding of human interleukin-1 (IL-1) receptor antagonist to natural and recombinant soluble and cellular IL-1 type I receptors.
    Svenson M; Nedergaard S; Heegaard PM; Whisenand TD; Arend WP; Bendtzen K
    Eur J Immunol; 1995 Oct; 25(10):2842-50. PubMed ID: 7589081
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Soluble type II interleukin 1 (IL-1) receptor binds and blocks processing of IL-1 beta precursor and loses affinity for IL-1 receptor antagonist.
    Symons JA; Young PR; Duff GW
    Proc Natl Acad Sci U S A; 1995 Feb; 92(5):1714-8. PubMed ID: 7878046
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Keratinocyte Integrin α3β1 Promotes Secretion of IL-1α to Effect Paracrine Regulation of Fibroblast Gene Expression and Differentiation.
    Zheng R; Longmate WM; DeFreest L; Varney S; Wu L; DiPersio CM; Van De Water L
    J Invest Dermatol; 2019 Sep; 139(9):2029-2038.e3. PubMed ID: 30878678
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 soluble receptor and hindered by type I interleukin-1 soluble receptor.
    Burger D; Chicheportiche R; Giri JG; Dayer JM
    J Clin Invest; 1995 Jul; 96(1):38-41. PubMed ID: 7615809
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intracellular IL-1 receptor antagonist is elevated in human dermal fibroblasts that overexpress intracellular precursor IL-1 alpha.
    Higgins GC; Wu Y; Postlethwaite AE
    J Immunol; 1999 Oct; 163(7):3969-75. PubMed ID: 10490999
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intracellular IL-1 receptor antagonist type 1 inhibits IL-1-induced cytokine production in keratinocytes through binding to the third component of the COP9 signalosome.
    Banda NK; Guthridge C; Sheppard D; Cairns KS; Muggli M; Bech-Otschir D; Dubiel W; Arend WP
    J Immunol; 2005 Mar; 174(6):3608-16. PubMed ID: 15749898
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interleukin-1 beta, interleukin-1 receptor antagonist, and soluble interleukin-1 receptor type II secretion in chronic fatigue syndrome.
    Cannon JG; Angel JB; Abad LW; Vannier E; Mileno MD; Fagioli L; Wolff SM; Komaroff AL
    J Clin Immunol; 1997 May; 17(3):253-61. PubMed ID: 9168406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.